Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin

Leukemia

Volumn 14, Issue 1, 2000, Pages 129-135

  Schnell, R ^a   Vitetta, E ^b   Schindler, J ^b   Borchmann, P ^a   Barth, S ^a   Ghetie, V ^b   Hell, K ^b   Drillich, S ^a   Diehl, V ^a   Engert, A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

CD25 antigen; Clinical trial; Hodgkin's lymphoma; Immunotoxins

Indexed keywords

IMMUNOTOXIN; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY; RICIN A;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEGLYCOSYLATION; DISULFIDE BOND; DYSPNEA; EDEMA; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LUNG INSUFFICIENCY; MALE; MAXIMUM PERMISSIBLE DOSE; MUSCLE WEAKNESS; MYALGIA; PRIORITY JOURNAL; REMISSION; STEREOSPECIFICITY;

EID: 0033978156     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401626     Document Type: Article

References (55)

1. De Vita VT, Molloy Hubbard S. Hodgkin's lymphoma. New Engl J Med 1983; 328: 560-565.
2. Longo IL, Young RC, Wesley M. Twenty years of MOPP therapy for Hodgkin's lymphoma. J Clin Oncol 1986; 4: 1295-1306.
3. Riethmüller G, Schneider-Gaedicke E, Schlimok G, Schmiegel W, Raab R, Hoeffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte R and the German Cancer Aid. 1 7-1A Study Group. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma. Lancet 1994; 343: 1177-1183.
4. Ro DC, Griffin JD, Belvin M, Blaettler WA, Lambert JM, Ritz J. Anti-My9-blocked ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Bload 1991; 77: 2404-2412.
5. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, Ritz J, Nadler LM. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-rell lymphoma. New Engl J Med 1991; 325: 1525-1533.
6. Kanzler H, Hansmann M-L, Kapp U, Wolf J, Diehl V, Rajewsky K, Kueppers R. Molecular single cell analysis demonstrates the derivation of a peripheral blood derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient. Blood 1996; 87: 3429-3436.
7. Wolf J, Kapp U, Bohlen H, Kornacker M, Schoch C, Stahl B, Muecke S, von Kalle C, Fonatsch C, Schaefer HE, Hansmann M-L, Diehl V. Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin/Reed-Sternberg cells. Blood 1996; 87: 3418-3428.
8. Simonsson B. Treatment of minimal residual disease in acute myelogenous leukemia (AML): focus on immunotherapeutic options. Leukemia 1996; 10 (Suppl. 2): 44-52.
9. Grossbard ML, Gribben JG, Freedman AS, Lambert J, Kinsella J, Rabinowe S, Eliseo L, Taylor J, Blatter W, Epstein C, Nadler L. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 1993; 81: 2263-2271.
10. Schnell R, Barth S, Diehl V, Engert A. Hodgkin's disease. Future treatment strategies: fact or fiction. In Diehl V (ed). Baillières Clinical Haematology. Baillière Tindall: London, 1996, pp 573-593.
11. Hsu SM, Jaffe ES. Leu M1 and peanut agglutinin stain the neoplastic cells of Hodgkin's lymphoma. Am J Clin Pathol 1984; 82: 29-32.
12. Hsu SM, Ho YS, Hsu PL. Effect of monoclonal antibodies anti-2H9, anti-IRac, and anti-HeFi-1 on the surface antigens of Reed-Sternberg cells. J Natl Cancer Inst 1987; 79: 1091-1097.
13. Stein H, Mason DY, Gerdes J, O'Conner N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, Schwarting R, Lennert K. The expression of the Hodgkin's-disease-associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Sternberg-Reed cells and histocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848-858.
14. Agnarsson BA, Kadin ME. The immunophenotype of Reed-Sternberg cells. A study of 50 cases of Hodgkin's lymphoma using fixed frozen tissue. Cancer 1989; 63: 2083-2087.
15. Kennedy IC, Hart DN, Colls BM. Nodular sclerosing, mixed cellularity and lymphocyte-depleted variants of Hodgkin's lymphoma are probable dendritic cell malignancies. Clin Exp Immunol 1989; 76: 324-331.
16. Delabie J, Ceuppens JL, Vandenberghe P, de Boer M, Coorevits L, de Wolf-Peeters C. The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's lymphoma and contributes to the stimulating capacity of Hodgkin's lymphoma-derived cell lines. Blood 1993; 82: 2845-2852.
17. Barth S, Schnell R, Diehl V, Engert A. Development of immunotoxins for potential clinical use in Hodgkin's disease. Ann Oncol 1996; 7 (Suppl. 4): 135-141.
18. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 1993; 73: 5-8.
19. Kreitman RJ, Pastan I. Recombinant single-chain immunotoxins against T and B cell leukemias. Leuk Lymphoma 1994; 13: 1-10.
20. Strauchen JA, Breakstone BA. IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. Am J Pathol 1987; 126: 506-512.
21. Engert A, Martin G, Amlot P, Wijdenes J, Diehl V, Thorpe P. Immunotoxins constructed with CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent antitumor effects against human Hodgkin cells in vitro and solid Hodgkin tumors in mice. Int J Cancer 1991; 49: 450-456.
22. Winkler U, Gottstein C, Schön G, Kapp U, Wolf J, Hansmann ML, Bohlen H, Thorpe P, Diehl V, Engert A. Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins. Blood 1994; 83: 466-475.
23. Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig MT, Drillich S, Schön G, Bohlen H, Tesch H, Hansmann ML, Barth S, Schindler J, Ghetie V, Uhr J, Vitetta E. A phase I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 1997; 89: 403-410.
24. Thorpe PE, Wallace PM, Knowles PP, Relf MG, Browmn ANF, Watson GJ, Blakes DC, Newell DR. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res 1988; 48: 6396-6403.
25. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
26. Merz H, Malisius R, Mannweiler S, Zhou R, Hartmann W, Orscheschek K, Moubayed P, Feller AC. ImmunoMax. A maximized immunohistochemical method for the retrieval and enhancement of hidden antigens. Lab Invest 1995; 73: 149-156.
27. Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, Herdt J, Kopp WC, Rager H, Steinberg SM, Ghetie V, Schindler J, Uhr JW, Wittes RE, Vitetta ES. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood 1995; 85: 3457-3465.
28. Schumaker RC. A basic interactive complex program for statistical and pharmacokinetic analysis of data. Drug Metab Rev 1986; 17: 331-342.
29. Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D, Ghetie V, Uhr J, Thorpe P. Phase-I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 1991; 51: 4052-4058.
30. Amlot P, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, Ramillo O, Thorpe P, Uhr J, Vitetta ES. A phase I study of an anti-CD22-deglycosylated ricin A-chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993; 82: 2624-2633.
31. Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD, Stetler-Stevenson M, Jain V, Jaffe ES, Solomon D, Lush RM, Senderowilz A, Ghetie V, Schindler J, Uhr JW, Vitetta ES. A phase I study of bolus vs. continuous infusion of the anti-CD19 immunotoxin, IgG-HL37-dgA in patients with B cell lymphoma. Blood 1996; 88: 1188-1197.
32. Vitetta ES, Thorpe PE, Uhr JW. Immunotoxins: magic bullets or misguided missiles? Immunol Today 1993; 14: 252-259.
33. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-2466.
34. Mansfield E, Amlot P, Pastan I, FitzGerald DJ. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood 1997; 90: 2020-2026.
35. Woodard SL, Fraser SA, Winkler U, Jackson DS, Kam CM, Powers JC, Hudig D. Purification and characterization of lymphocyte chymase I, a granzyme implicated in perforin-mediated lysis. J Immunol 1998; 160: 4988-4993.
36. Kreitman RJ, Chaudhary VK, Kozak RW, FitzGerald DJP, Waldmann TA, Pastan I. Recombinant toxins containing the variable domains of the anti-tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocylic leukemia. Blood 1992; 80: 2344-2352.
37. Kreitman RJ, Chaudhary VK, Waldmann TA, Hanchard B, Cranston B, FitzGerald DJP, Pastan I. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or Diphtheria toxin toward lymphocytes from patients with adult T cell leukemia. Leukemia 1993; 7: 553-562.
38. 486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 1994; 84: 1765-1774.
39. 389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998; 91: 399-405.
40. Williams DP, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, Strom TB, Murphy JR. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Prot Eng 1987; 1: 493-498.
41. LeMaistre CF, Craig FE, Meneghetti CM, McMullin B, Parker K, Reuben J, Boldt DH, Rosenblum M, Woodworth T. Phase-I trial of a 90-mmute infusion of the fusion toxin DAB486IL-2 in hematological cancers. Cancer Res 1993; 53: 3930-3934.
42. 486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992; 79: 2547-2554.
43. 486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 1494; 73: 1276-1285.
44. Tazzari PL, Bolognesi A, de Totero D, Falini B, Lemoli RM, Soria MR, Pileri S, Gobbi M, Stein H, Flenghi L, Martelli MF, Stirpe F. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's lymphoma and CD30+ lymphoma: in vitro evaluation. Br J Haematol 1992; 81: 203-211.
45. Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, Dürkopp H. Response of refractory Hodgkin's lymphoma to monoclonal anti-CD30 immunotoxin. Lancet 1992; 339: 1195-1196.
46. Falini B, Pasqualucci L, Flenghi L, Bologneri A, Kadin M, Stein H, Martinelli MF, Stirpe F. Anti-CD30 inimunotoxins: experimental and clinical studies. Abstracts of the Fourth International Symposium on Immunotoxins. 1995, 160A.
47. Engert A, Burrows F, Jung W, Tazzari PL, Stein H, Pfreundschuh M, Diehl V, Thorpe P. Evaluation of ricin A-chain-containing inimunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's lymphoma. Cancer Res 1990; 50: 84-88.
48. Horn-Lohrens O, Tiemann M, Lange H, Kobarg J, Hafner M, Hansen H, Sterry W, Parwaresch RM, Lemke H. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer 1995; 60: 539-544.
49. Schnell R, Linnartz C, Schön G, Katouzi A, Bohlen H, Horn-Lohrens O, Parwaresch R, Diehl V, Lemke H, Engert A. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Int J Cancer 1995; 63: 238-244.
50. Engert A. Gottstein C, Bohlen H, Winkler U, Schön G, Manske O, Schnell R, Diehl V, Thorpe P. Cocktails of ricin A-chain immunotoxins against different antigens of Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice. Int J Cancer 1995; 63: 304-309.
51. Katz FE, Janossy G, Cumber A, Ross W, Blacklock HA, Tax W, Thorpe PE. Elimination of T cells from human peripheral blood and bone marrow using a cocktail of three anti-T cell immunotoxins. Br J Haematol 1987; 67: 407-411.
52. Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES. The antitumor activity of an anti-CD 22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood 1992; 80: 2315-2320.
53. Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, Kloft M, Pfreundschuh M. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 1997; 89: 2042-2047.
54. Barth S, Engert A. Recombinant immunotoxins for the treatment of Hodgkin's lymphoma. Leuk Lymphoma 1998; 29 (Suppl. 1): O-10.
55. Klinika A, Roovers RC, Barth S, Bot F, Engert A, Arends JW, Hoogenboom HR. Human anti-CD30 phage antibody by guided selection for imunotherapy of Hodgkin's lymphoma. Leuk Lymphoma 1998; 29 (Suppl. 1): P-112.